Epidemiology of esophageal cancer - an overview article

Kollárová, Helena; Máchová, L; Horáková, D; Janoutová, Gabriela; Janout, Vladimí­r

doi:10.5507/bp.2007.003

Cited by 95 publications

(84 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Esophageal cancer remains one of the most fatal types of cancer worldwide, with an incidence on the rise (9). Despite clinical advances, esophageal cancer remains one of the leading causes of cancer-associated mortality (31).…”

Section: Discussionmentioning

confidence: 99%

“…A recent study demonstrated that dietary behavior is also associated with esophageal cancer (8). Despite recent advances in surgical techniques and treatment strategies for esophageal cancer, the five-year survival rate post-surgery is only 20-30% (9). Furthermore, conventional chemotherapeutic drugs used in esophageal cancer treatment, including cisplatin, often have severe side effects that limit their efficacy (10).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Terrein performs antitumor functions on esophageal cancer cells by inhibiting cell proliferation and synergistic interaction with cisplatin

Zhu

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract.Terrein is a bioactive fungal metabolite isolated from Aspergillus terreus. Besides being a melanogenesis inhibitor, previous studies have revealed that terrein has antiproliferative effects on a number of types of cancer tumors. In the present study, the inhibitory effect of terrein on esophageal cancer was evaluated and the possible underlying mechanisms were investigated. The results revealed that terrein inhibited the proliferation of Eca109 esophageal cancer cells in a dose-and time-dependent manner. Mechanistically, terrein treatment led to the G 2 /M phase arrest of Eca109 cells by indirectly regulating cyclin B1 and phosphorylating the cell division cycle protein 2 genes. Notably, terrein exhibited a synergistic effect on Eca109 cells when combined with cisplatin, which is a commonly used chemotherapeutic drug. Taken together, these findings indicate that terrein suppresses the proliferation of esophageal cancer cells, and may prove to be a novel therapeutic approach for the treatment of esophageal cancer via inhibiting the proliferation of cancer cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Terrein performs antitumor functions on esophageal cancer cells by inhibiting cell proliferation and synergistic interaction with cisplatin

Zhu

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Seventy-five percent of patients die within one year after diagnosis (Hiyama et al, 2007), while five-year survival is less than 5%. The risk of developing esophageal cancer increases with age, and the highest incidence has been reported to be at the age of 50 to 70 years (Kollarova et al, 2007). Most patients diagnosed with esophageal cancer live in the so-called Asian esophageal cancer belt, including parts of northern Iran (Lam et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Loss of heterozygosity on chromosome 5 in Iranian esophageal cancer patients

Attaran-Bandarabadi

Ziaee

Yazdanbod³

et al. 2011

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. There is a high incidence of esophageal squamous cell carcinoma (ESCC) in Iran. Non-functionality of some tumor suppressor genes has been reported in esophageal cancer. Loss of heterozygosity on chromosome 5 has also been reported in esophageal carcinomas. We assessed loss of heterozygosity along a region of the long arm of chromosome 5 (5q), from 5q23.1 to 5q23.2, by PCR amplifying DNA fragments of tumor tissues from patients with ESCC and their corresponding normal samples. The PCR products were electrophoresed on 6% non-denaturing polyacrylamide gels, and band intensity was shown by silver staining. Of 40 patients with ESCC, 27, 25 and 36% of informative cases showed allelic losses at microsatellite markers D5S1384, D5S1478 and D5S1505, respectively. Two of the 40 patients studied had microsatellite instability at marker D5S1384. Based on the fact that loss of heterozygosity with more than 22% incidence for a specific marker cannot be regarded as a random event, we add support to previous reports concerning the presence of tumor suppressor genes in this chromosome region and that they affect esophageal cancer Loss of heterozygosity in esophageal cancer development. According to the data in NCBI UniSTS, the PCR product size of human DNA with primers of the D5S1505 marker ranges from 243 to 275 bp, containing about 20 repeats of the TAGA tetranucleotide, while the amplicon size of one allele of one of our cases was 207 bp, with about 10 repeats of the TAGA tetranucleotide, which would be the shortest sequence reported so far.

show abstract

“…1 Five-year survival is less than 5%. 2 Squamous Cell Carcinoma: The gross appearance varies according to whether it is detected in an early or an advanced stage of the disease. Among early SCC, polypoid, plaque-like, depressed and occult lesions have been described.…”

mentioning

confidence: 99%